Sign Out
Dacatec (Daclatasvir) must not be administered as monotherapy.
Dacatec (Daclatasvir) must be administered in combination with other medicinal products for the treatment of chronic HCV infection.
Should concomitant use of amiodarone be considered necessary it is recommended that patients are closely monitored when initiating Dacatec (Daclatasvir) in combination with sofosbuvir. All patients receiving Dacatec (Daclatasvir) and sofosbuvir in combination with amiodarone with or without other drugs that lower heart rate should also be warned of the symptoms of bradycardia and heart block and should be advised to seek medical advice urgently should they experience them.
Dacatec (Daclatasvir) has not been studied in patients with HCV genotypes 5 and 6, and no regimen recommendation can be given.
